Chr t(15;17)
|
Acute Promyelocytic Leukemia
|
Chr t(15;17)
|
Acute Promyelocytic Leukemia
|
arsenic trioxide Sensitive: A1 - Approval
|
arsenic trioxide Sensitive: A1 - Approval
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
arsenic trioxide Sensitive: A1 - Approval
|
arsenic trioxide Sensitive: A1 - Approval
|
No biomarker
|
Acute Promyelocytic Leukemia
|
No biomarker
|
Acute Promyelocytic Leukemia
|
gemtuzumab ozogamicin Sensitive: A2 - Guideline
|
gemtuzumab ozogamicin Sensitive: A2 - Guideline
|
No biomarker
|
Acute Promyelocytic Leukemia
|
No biomarker
|
Acute Promyelocytic Leukemia
|
cytarabine + daunorubicin Sensitive: A2 - Guideline
|
cytarabine + daunorubicin Sensitive: A2 - Guideline
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
tretinoin + arsenic trioxide Sensitive: C3 – Early Trials
|
tretinoin + arsenic trioxide Sensitive: C3 – Early Trials
|
STAT5b-RARA fusion
|
Acute Promyelocytic Leukemia
|
STAT5b-RARA fusion
|
Acute Promyelocytic Leukemia
|
DCAG Sensitive: C4 – Case Studies
|
DCAG Sensitive: C4 – Case Studies
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
cytarabine + idarubicin hydrochloride + tretinoin Sensitive: C4 – Case Studies
|
cytarabine + idarubicin hydrochloride + tretinoin Sensitive: C4 – Case Studies
|
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression
|
Acute Promyelocytic Leukemia
|
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression
|
Acute Promyelocytic Leukemia
|
cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies
|
cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea Sensitive: C4 – Case Studies
|
PML-RARA T285I
|
Acute Promyelocytic Leukemia
|
PML-RARA T285I
|
Acute Promyelocytic Leukemia
|
venetoclax Sensitive: C4 – Case Studies
|
venetoclax Sensitive: C4 – Case Studies
|
ZBTB16-RARA fusion
|
Acute Promyelocytic Leukemia
|
ZBTB16-RARA fusion
|
Acute Promyelocytic Leukemia
|
chidamide Sensitive: D – Preclinical
|
chidamide Sensitive: D – Preclinical
|
STAT5b-RARA fusion
|
Acute Promyelocytic Leukemia
|
STAT5b-RARA fusion
|
Acute Promyelocytic Leukemia
|
chidamide Sensitive: D – Preclinical
|
chidamide Sensitive: D – Preclinical
|
NPM-RARA fusion
|
Acute Promyelocytic Leukemia
|
NPM-RARA fusion
|
Acute Promyelocytic Leukemia
|
chidamide Sensitive: D – Preclinical
|
chidamide Sensitive: D – Preclinical
|